AUTHOR INDEX

Annas, G.D., 2

Benowitz, N.L., 250
Bialous, S.A., 291, 301
Boyle, D.A., 70
Breed, C.D., 109
Browning, K.K., 268
Burns, D.M., 244
Butler, J., S1:3

Chan, S., 284, 301
Cooley, M.E., 233

Danao, L., 233
DeMeyer, E., 118
Devine, H., 118
DiFranza, J.R., 261

Edwards, S.J., S1:19

Fitch, M.I., 40, S1:1
Fraser, M.C., 1
Froelicher, E.S., 250, 276

Gale, D.M., 193
Geller, A.C., 2
Gemmill, R., 162
Gordon, A.N., S1:3

Halpern, A.C., 22
Hartley, C., 250
Hollis, G., 32
Huang, D., 154
Hutchinson, K.M., 276
Hwu, W-J., 22

Idell, C.S., 162

Kaufman, N., 291

Lam, T.H., 284
Lamb, L.A., 22
Liu, K., 217
Loescher, L.J., 1

Maguire-Eisen, M., 43
Mahon, S.M., 52
Mautner, B., 154

Muehlbauer, P.M., 180, 206

Percival, J., 301

Recio, A., 32
Richmond, E., 62

Sarna, L., 231, 233, 291, 301
Schmidt, K.V., 153, 169
Schuchter, L., 32
Schwartzentruber, D.J., 206
Shannon-Dorey, K., 142
Shelton, B.K., 133
Sohn, M., 250
Stull, D.M., 90

Vargo, N., 12
Viele, C.S., 98
Viner, J.L., 62

Wellman, R.J., 261
Wewers, M.E., 268
Wolfe, V., 142
Wood, B.A., 169
Wujcik, D., 81, 83

SUBJECT INDEX

Absorption, of nicotine, 244
Access to tobacco, minors and, 263, 294–295
"Addiction-free cigarettes," 253
Adolescent tobacco use
  access and, 263, 294–295
  advertising and, 264
  epidemiology, 262
  legal issues, 261–262
  mass media campaigns, 265
  nursing involvement and, 265–266
  pricing and, 263–264
  public health response, 263–265
  relative risks for, 246
  risks for cancer survivors, 262–263
  school health programs, 264
  smoking cessation and, 265
  smoking restrictions and, 264
Advertising, of tobacco products
  adolescents and, 264
  historical aspects, 233, 234, 235
  targeting of, 279–280, 292
  total bans on, 294
Advocacy groups, 265
Africa, tobacco control in, 305
African-Americans
  advertising of tobacco products to, 279–280
  nicotine metabolism in, 254
  poverty and, 280–281
Age, lung function and, 248
Agency for Healthcare Research and Quality (AHRQ), clinical practice guidelines, 269–270, 272–273
American Cancer Society, mass media campaigns, 265
Asia, tobacco control in, 304–305
Assessment tools, in clinical practice, 270–271B

Bidis, 236
Bisexuals, 278
Brain, nicotine levels in, 253
Breast cancer, 279
Bronchitis, 276, 285
Bupropion SR (Zyban), 257, 258, 269C

Cancer. *See also* Lung cancer
  adolescent survivors, smoking risks for, 262–263
  breast, 279
  control strategies, 281
  future smoking cessation research, 274
  poverty and, 280
  risk, smoking cessation and, 240–241
  smoking cessation in, 273–274
  tobacco-attributable, 239–240, 268
  tobacco control policies and, 291–292
Cancer deaths, tobacco-related, 233, 250
Carbon monoxide monitor, 270–271
Carcinogens, exposure to, 292
Cerebrovascular disease, age-specific relative risks, 246
CHD. *See* Coronary heart disease
Childhood cancer survivors, smoking risks for, 262–263
Children
  second-hand smoke and, 285–288
  tobacco-related diseases and, 277
China, 234, 235
Chronic obstructive pulmonary disease (COPD)
  age-specific relative risks, 246
  cigarette smoking and, 239, 245, 248
Cigarettes. *See also* Smoking
  "addiction-free," 253
  cancers-related to, 236
  clove, 253
  "light," 252–253
  nicotine content of, 252
  packaging/labeling, 294
  pricing for, 263–264
  smoke from, 252
  tobacco in, 244
  world-wide usage of, 236
Cigars, 236. *See also* Smoking
Clove cigarettes, 253
Conditioning, nicotine dependence and, 256
COPD. *See* Chronic obstructive pulmonary disease
Coronary heart disease (CHD)
  cigarette smoking and, 239, 248
  relative risks for smokers, 245, 246

risk, smoking cessation and, 247–248
risk factors, 247–248
Cost-effectiveness, of smoking cessation programs, 269
Cotinine, 254–255, 271
Cultural differences, in tobacco-related diseases, 276–277D

Deaths, tobacco-related
cancer and, 250, 268
cigarette smoking and, 235, 248, 250
from second-hand smoke, 284
Dependence, nicotine, 254–246. *See also specific aspects of*
assessment of, 256–257
chronicity, 269
deaths related to, 261
dose-response relationship, 269
environmental rewards, 256
nursing implications, 258–259
prevalence, 256
psychological rewards, 256
treatment, 257–258, 269
Diseases, tobacco-related. *See also specific tobacco-related diseases*
advertising targets and, 279–280
children, 277
cultural differences in, 276–277
ethnic minorities and, 278
four-stage model of, 235, 238
geographic regions and, 238
nursing implications for, 281–282
prevention, resources for, 281
risk measurement for, 245–247
sociodemographic differences in, 276–277
women and, 278
Distribution, of nicotine, 253
Drug addiction, 251
Drug dependence, 251
Drug habit, 251
Drug-seeking behavior, 251
Drug-taking behavior, 251E

Economic burden, of cigarette smoking, 250
Education
for nurses, 302
to prevent second-hand smoke exposure, 285–287
of public, nursing role in, 241
resources, 281
Emphysema, 276
ENMAT (European Nurses and Midwives Against Tobacco), 304
Environmental tobacco smoke. *See* Second-hand smoke
Ethnicity
adolescent cigarette smoking and, 262
advertising of tobacco products and, 279–280
nicotine metabolism differences, 254
poverty and, 280–281
tobacco-related diseases and, 277, 278
Europe, tobacco control in, 303–304
European Nurses and Midwives Against Tobacco (ENMAT), 304
Excess death rates, 246F

Fagerstroem Questionnaire for Nicotine Dependence, 256, 257
FCTC (Framework Convention on Tobacco Control), 291, 293–295
Females
adolescent cigarette smoking, 262
breast cancer and, 279
lung cancer and, 278, 279
lung cancer deaths, 250
nicotine dependence and, 261
prevalence of smoking in, 268
smoking among, 236
tobacco-related diseases and, 278
Fetal exposure, to nicotine, 277
First second with a maximal effort (FEV1), 248
Framework Convention on Tobacco Control (FCTC), 291, 293–295G

Gays, 278H

Habitual behavior, vs. drug dependence, 251
Half-life, of nicotine, 254
Health care costs, tobacco-related, 241
Health care medical expenditures, smoking-attributable, 250
Health disparities, 276
Healthy People 2010, 270
Heart disease, 239
Hedonic homeostatic dysregulation, 255
HIV/AIDS, 278, 306
Homeless persons, tobacco usage by, 278–279
Hong Kong, tobacco control in, 305
Hooked on Nicotine Checklist, 265
Hospitalization, smoking cessation during, 256–257I

ICN (International Council of Nurses), 301
Illicit drug use, 279
Illicit trade, in tobacco products, 294
International Council of Nurses (ICN), 301
Internet-based smoking cessation programs, 273–274K

Kreteks, 236L

Labeling, of tobacco products, 294
Latin America, tobacco control in, 305–306
Legal issues, adolescent tobacco use, 261–262
Lesbians, 278
"Light cigarettes," 252–253
Litigation, pricing of tobacco products and, 263–264
Lung cancer
age-adjusted death rates, 279
age-specific relative risks, 246
cigarette smoking and, 239, 246–247, 248
deaths from, 234, 250
epidemic of, 244–245
implementing AHRQ guidelines in, 272–273
incidence, in different countries, 239–240
low-tar vs. high-tar cigarettes, 253
mortality rates, 268
perceptions of, 296–297
postdiagnosis smoking, 268–269
prevention, smoking cessation and, 242
risk, smoking cessation and, 247
smoking and, 276
smoking cessation efficacy in, 271
women and, 278, 279
Lung function, age and, 248M

Males
adolescent cigarette smoking, 262
lung cancer deaths, 250
nicotine dependence and, 261
prevalence of smoking in, 268
Malignancies, smoking-related, 233–234. *See also* Cancer; Lung cancer
Mass media campaigns, 265
Master Settlement Agreement, 264, 295
Men. *See* Males
Mental illness, 279
Metabolism, of nicotine, 253–254
Middle ear infection, 285
Morbidity, tobacco-related, 239
Mortality, tobacco-related. *See* Deaths, tobacco-related
Motivation, for smoking cessation, 270, 271N

Neuroadaptation, 255

Neurotransmitters, nicotine effects on, 254
Nicotine. *See also* Dependence, nicotine
  absorption, 244, 252–253
  as addictive drug, 251
  blood concentrations, 252
  content, of cigarettes, 252
  dependence, 254–246
  distribution, 253
  elimination of, 253–254
  fetal exposure to, 277
  metabolism of, 253–254
  neurochemical effects, 254, 255
  pharmacodynamics, 251, 254
  pharmacokinetics, 251–254
  self-regulation by smokers, 252
  tolerance, 255
  tooth decay and, 277
  withdrawal, 251, 254–256
Nicotine-N'-oxide, 253
Nicotine replacement therapy (NRT), 254, 257–258
Nicotinic cholinergic receptors, 254
NRT (nicotine replacement therapy), 254, 257–258
Nurse clinicians, as smoking cessation interventionists, 271–272
Nursing education, tobacco-related, 302
Nursing literature, on tobacco, 301–302O

Oncology health professionals, tobacco control and, 296
Oncology Nursing Society (ONS), 296P

Packaging, of tobacco products, 294
Passive smoke. *See* Second-hand smoke
pH, of tobacco smoke, 252
Pharmacodynamics, of nicotine, 251
Pharmacokinetics, of nicotine, 251–254
Pharmacotherapy, for smoking cessation, 257, 258, 269
Pipes, 236
Politics, tobacco control policies and, 296–297
Poverty, 280–281
Prevalence, of tobacco usage, 233–234
Pricing, of tobacco products, 263–264, 293
Productivity losses, mortality-related, attributable to smoking, 250
Promotion. *See* Advertising, of tobacco products
Public health response, to adolescent tobacco usage, 263–265
Pulmonary system, nicotine distribution and, 253Q

"Quit with onset of disability," 248R

Race
  adolescent cigarette smoking and, 262
  differences in nicotine metabolism, 254
Relative risks
  age-specific, 246
  for all cause mortality, 245–246
  from cigarette smoking, 245
  definition of, 245
  of lung cancer in smokers, 246–247
  for youth tobacco usage, 246
Research, nursing, 241, 242, 302–303S

Schizophrenia, 279
School health programs, 264
Second-hand smoke
  cancers-related to, 236
  chemicals in, 284
  children and, 277
  deaths from, 284
  education interventions, 285–287
  elimination, effects from, 284
  health effects from, 284–285
  lung cancer deaths and, 234
  nursing practice implications, 287–288
  nursing research implications, 288
  protection from exposure to, 293–294
Self-regulation of nicotine, 252, 255
Smoke, tobacco
  chemicals in, 284
  pH of, 252
Smokeless tobacco
  blood nicotine levels and, 252
  cancers-related to, 236
  usage, prevalence of, 234, 278
  world-wide usage, 236
Smoking
  adolescent, 262
  after lung cancer diagnosis, 268–269
  COPD and, 248
  coronary heart disease and, 247
  deaths related to, 248, 250
  disease burden from, 245–246
  disease burden of, 244
  economic burden of, 250
  lung cancer and, 246–247
  positive rewards of, 254
  prevalence, world-wide, 236, 237–238
  relative risks of, 245
  self-regulation of nicotine and, 252, 255
Smoking cessation
  adolescents and, 265
  barriers, 273
  for cancer populations, 273–274
  coronary heart disease and, 247–248
  efficacy in cancer populations, 271
  evidence-based, 269–270
  future research, 274
  during hospitalization, 256–257
  implementing AHRQ guidelines, 272–273
  interventionists, nurse clinicians as, 271–272
  lung cancer rate reductions, 247
  lung cancer risk and, 247
  lung function and, 248
  motivation for, 270
  nicotine withdrawal and, 255–256
  nursing implications/involvement, 258–259, 302–303
  nursing role in, 241–242
  reduction in tobacco-related mortality and, 240–241
Smoking restrictions, 264
Smuggling, of tobacco products, 294
Snuff, 236
Sociodemographic differences, in tobacco-related diseases, 276–277
Sponsorship of events, 294
Sudden infant death, 285
Surgeon General's Report, criteria for drug dependence, 251
Sweden, tobacco control in, 304T

Taxation, of tobacco products, 263–264, 293
Teenage tobacco usage. *See* Adolescent tobacco use
Tobacco control policies. *See also* Smoking cessation
  cancer and, 291–292
  international nursing involvement, 303–307
  Master Settlement Agreement, 264, 295
  nursing practice implications, 297
  oncology health professionals and, 296
  political processes and, 296–297
  published literature, 301–303
  tobacco industry and, 292–293
  WHO Framework Convention, 291, 293–295
Tobacco epidemic
  deaths from, 235–236, 239
  disease and, 235

prevalence of, 233–235
Tobacco industry, 292–293
Tobacco products. *See also specific tobacco products*
advertising, 264
advertising for, 233, 234, 235
cancer and, 239–240
cancer deaths and, 250
cancers related to, 236
dependence on (*See* Dependence, nicotine)
as global problem, 242
"habituating" usage, 250
historical aspects of use, 244
packaging/labeling, 294
per capita consumption, 244, 245
pricing, 263–264, 293
smoke from, 252
smuggling or illicit trade in, 294
taxation, 293
usage, world-wide, 236
world-wide usage, 236, 237–238
by youth (*See* Adolescent tobacco use)
Tooth decay, nicotine exposure and, 277
TRUTH campaign, 265, 295U

Underserved persons, 277
Upper respiratory cancer, cigarette smoking and, 239W

WHO. *See* World Health Organization
Withdrawal, nicotine, 251, 254–256
Women. *See* Females
World Health Organization (WHO)
European Partnership Project to Reduce Tobacco Dependence, 303–304
Framework Convention on Tobacco Control, 291, 293–295
second-hand smoke exposure policy, 285
four-stage model, 235, 238
tobacco use, initiation stages, 238Y

Youth tobacco usage. *See* Adolescent tobacco useZ

Zyban (bupropion SR), 257, 258, 269